MiNK Therapeutics, Inc.
NASDAQ:INKT · NASDAQ Capital Market
-$0.32 today
Vol 0.02M · Avg 0.05M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
87.8%
avg 1030.1%
ROIC
-195.5%
avg 149.3%
ROA
-87.7%
avg -450.0%
Analysis
ROE is currently the strongest return metric at 87.8% versus its period average of 1030.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jennifer S. Buell | Co-Founder, President, CEO & Director | $803,686.00 | — | 51 | $57,942.00 | 1.16% |
Terese C. Hammond | Head of Inflammatory & Pulmonary Diseases | — | — | — | — | — |
Melissa Orilall | Principal Financial Officer | — | — | 37 | $222.00 | <0.01% |
Garo H. Armen | Executive Chairman | — | — | 73 | $0.00 | <0.01% |
Austin Charette | Principal Accounting Officer | — | — | 37 | $40.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
8
$46,618.91
Net Sentiment
$46,618.91
Net selling
Most Active
Ryan Barbara
8 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 8 sells worth $46,618.91 over the last 12 months. That adds up to net selling of $46,618.91. Ryan Barbara was the most active insider with 8 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Equillium, Inc.
NASDAQ:EQ
$99.82M
vTv Therapeutics Inc.
NASDAQ:VTVT
$85.75M
OS Therapies Incorporated
AMEX:OSTX
$75.71M
Gain Therapeutics, Inc.
NASDAQ:GANX
$71.66M
Spruce Biosciences, Inc.
NASDAQ:SPRB
$71.19M
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
$66.38M
Outlook Therapeutics, Inc.
NASDAQ:OTLK
$50.19M
CervoMed Inc.
CRVO
$22.68M
Werewolf Therapeutics, Inc.
HOWL
$18.52M
IO Biotech, Inc.
IOBT
$885,690.00
Who manages INKT?
MiNK Therapeutics, Inc. (INKT) lists 5 active executives. The top listed executive is Terese C. Hammond, Head of Inflammatory & Pulmonary Diseases.
Are INKT insiders buying or selling?
Recent insider activity shows net buying of $19.97M.
Explore More
Continue the stock analysis
Jump to another research area for this company.